Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Palovarotene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    US FDA approves French drugmaker Ipsen's rare bone disorder drug
    US FDA approves French drugmaker Ipsen's rare bone disorder drug

    17 Aug 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-ipsens-rare-bone-disorder-drug-2023-08-16/

    REUTERS
    17 Aug 2023
    Share Share
    Ipsen says EC rejects marketing authorization for bone disorder drug
    Ipsen says EC rejects marketing authorization for bone disorder drug

    19 Jul 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/ipsen-says-european-commission-rejects-marketing-authorization-bone-disorder-2023-07-19/

    REUTERS
    19 Jul 2023
    Share Share
    FDA adcomm votes in favor of Ipsen's fibrodysplasia drug
    FDA adcomm votes in favor of Ipsen's fibrodysplasia drug

    29 Jun 2023

    // Katherine Lewin ENDPTS

    https://endpts.com/fda-adcomm-votes-in-favor-of-ipsens-fibrodysplasia-drug/

    Katherine Lewin ENDPTS
    29 Jun 2023
    Share Share
    Ipsen announces +ve outcome of FDA Advisory Committee on investig. palovarotene
    Ipsen announces +ve outcome of FDA Advisory Committee on investig. palovarotene

    28 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/29/2696672/0/en/Ipsen-announces-positive-outcome-of-FDA-Advisory-Committee-on-investigational-palovarotene-for-fibrodysplasia-ossificans-progressiva.html

    GLOBENEWSWIRE
    28 Jun 2023
    Share Share
    FDA reviewers on Ipsen's potential ultra-rare disease drug
    FDA reviewers on Ipsen's potential ultra-rare disease drug

    27 Jun 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/fda-reviewers-on-ipsens-potential-fibrodysplasia-drug-post-hoc-analysis-may-be-enough/

    Zachary Brennan ENDPTS
    27 Jun 2023
    Share Share
    Ipsen receives CHMP negative opinion, following re-examination of FOP treatment
    Ipsen receives CHMP negative opinion, following re-examination of FOP treatment

    26 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/26/2677082/0/en/Ipsen-receives-CHMP-negative-opinion-following-re-examination-of-potential-first-FOP-treatment-in-the-E-U.html

    GLOBENEWSWIRE
    26 May 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.